Company / R&D per Share
Denali Therapeutics Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.90
FY2025
5-year range
$1.60 / $3.12
FY2021-FY2025
Trend
+1.4%
vs FY2024
Sector context
#74 of 208
Health Care
What the data says
At $2.90, Denali Therapeutics Inc.'s r&d per share ranks #74 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 10 years, ranging from $0.79 in FY2019 to $11.78 in FY2016.
Based on SEC 10-K filings.
2.90 in FY2025 with a 5-year CAGR of +14.3%.
Declined from $3.12 to $2.90 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +18.6%
- 5-Year CAGR
- +14.3%
- 10-Year CAGR
- -
Sector benchmark
#74 of 208 in Health CareTop 36% of 208This company $2.90 Sector average $12.19
▼
-76.2% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 1.4% year-over-year.
- Ranks #74 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2016.
- Lowest r&d per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.90 | +1.4% |
| FY2024 | $2.86 | -8.1% |
| FY2023 | $3.12 | +79.3% |
| FY2022 | $1.74 | +8.4% |
| FY2021 | $1.60 | +7.8% |
| FY2020 | $1.49 | +89.2% |
| FY2019 | $0.79 | -9.1% |
| FY2018 | $0.87 | -82.6% |
| FY2017 | $4.98 | -57.8% |
| FY2016 | $11.78 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026